Richard Franklin - Pathfinder Cell President CEO, Secretary, Director
| PFND Stock | USD 0.0001 0.00 0.00% |
CEO
Dr. Richard L. Franklin, M.D., Ph.D., is President, Chief Executive Officer, Secretary, Director of Pathfinder Cell Therapy, Inc. He served as Executive Chairman of our company from October 2008 to September 2010, and as Chairman from June 2003 until September 2011. Dr. Franklin is a cofounder of our subsidiary, Pathfinder, LLC, and has served as its CEO, President and sole manager since its inception. Dr. Franklin is a director of Raptor Pharmaceuticals, Inc., a publicly traded drug development company. Dr. Franklin is founder, CEO and a director of Tarix Pharmaceuticals, a private company developing peptides for the treatment of ischemic stroke recovery, peripheral vascular disease, and diabetes. Dr. Franklin is founder and CEO of Tarix Orphan LLC, a company focused on the development of peptides to treat muscular dystrophy and Marfan syndrome since 2011.
| Age | 78 |
| Tenure | 13 years |
| Professional Marks | Ph.D |
| Phone | 617-245-0289 |
| Web | https://www.pathfindercelltherapy.com |
Pathfinder Cell Management Efficiency
The company has return on total asset (ROA) of (8.8876) % which means that it has lost $8.8876 on every $100 spent on assets. This is way below average. Pathfinder Cell's management efficiency ratios could be used to measure how well Pathfinder Cell manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 3 records | CEO Age | ||
| FACC Facp | NewAmsterdam Pharma | 67 | |
| Spiro Rombotis | Cyclacel Pharmaceuticals | 65 | |
| Markus MD | Monte Rosa Therapeutics | 53 | |
Management Performance
| Return On Asset | -8.89 |
Pathfinder Cell Therapy Management Team
Elected by the shareholders, the Pathfinder Cell's board of directors comprises two types of representatives: Pathfinder Cell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pathfinder. The board's role is to monitor Pathfinder Cell's management team and ensure that shareholders' interests are well served. Pathfinder Cell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pathfinder Cell's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Benson, CFO and Treasurer | ||
| Richard Franklin, President CEO, Secretary, Director | ||
| Joerg Gruber, Founder and Chairman |
Pathfinder Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Pathfinder Cell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -8.89 | |||
| Current Valuation | 7.41 M | |||
| Shares Outstanding | 667.16 M | |||
| EBITDA | (1.67 M) | |||
| Net Income | (1.39 M) | |||
| Cash And Equivalents | 4 K | |||
| Total Debt | 5.41 M | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (963 K) | |||
| Beta | 0.14 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Pathfinder Pink Sheet
Pathfinder Cell financial ratios help investors to determine whether Pathfinder Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pathfinder with respect to the benefits of owning Pathfinder Cell security.